查看文章

During the first decades of fludeoxyglucose (FDG)-PET, the relative nonspecificity and the incidental false positive findings in patients with cancer caused by infectious or inflammatory processes were considered a nuisance. However, the usefulness and benefits have now been recognized outside the realm of malignancies: it is well known that molecular and cellular processes of inflammation create potential grounds for molecular targeted imaging, and the role of FDG-PET in the diagnosis and assessment of inflammation has been established in a multitude of clinical domains. 1–3 The fundamental basis for increased cellular uptake of FDG, the so-called Warburg